NCT00820924 - Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Neoplasms, Breast

Interventions

DRUG

LAPATINIB

LAPATINIB 1500MG ORAL DOSE DAILY

Trial Locations (10)

GSK Investigational Site, Rozzano (MI)

GSK Investigational Site, Milan

GSK Investigational Site, Bergamo

GSK Investigational Site, Udine

GSK Investigational Site, Rimini

GSK Investigational Site, Livorno

GSK Investigational Site, Prato (PO)

GSK Investigational Site, Ancona

GSK Investigational Site, Perugia

GSK Investigational Site, London